Celon Pharma SA

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: PLCLNPH00015

PLN

19.98

-0.02 (-0.1%)

Dec 12

WAR

Click here to see other stocks

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

BIOTON SA

Biogened SA

Celon Pharma SA

Ryvu Therapeutics SA

Captor Therapeutics SA

Synthaverse SA

Bioceltix SA

Molecure SA

E-shopping Group SA

Why is Celon Pharma SA ?

Poor Management Efficiency with a low ROE of 1.43%

The company has been able to generate a Return on Equity (avg) of 1.43% signifying low profitability per unit of shareholders funds

Poor long term growth as Operating profit has grown by an annual rate -17.49% of over the last 5 years

With ROE of -0.77%, it has a risky valuation with a 3.08 Price to Book Value

Over the past year, while the stock has generated a return of -18.78%, its profits have risen by 91.9%

Below par performance in long term as well as near term

Along with generating -18.78% returns in the last 1 year, the stock has also underperformed Poland WIG in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Celon Pharma SA for you?

Medium Risk, Low Return

Absolute

Risk Adjusted

Volatility

Celon Pharma SA

-16.92%

0.91

32.46%

Poland WIG

39.24%

1.84

20.48%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

17.90%

EBIT Growth (5y)

-17.49%

EBIT to Interest (avg)

-10.38

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.10

Sales to Capital Employed (avg)

0.46

Tax Ratio

23.15%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

1.17%

ROE (avg)

1.43%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.08

EV to EBIT

-1158.12

EV to EBITDA

23.37

EV to Capital Employed

3.23

EV to Sales

4.22

PEG Ratio

Dividend Yield

ROCE (Latest)

-0.14%

ROE (Latest)

-0.77%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -35.99% (YoY

0What is not working for the Company

NO KEY NEGATIVE TRIGGERS

Here's what is working for Celon Pharma SA

Raw Material Cost

Fallen by -35.99% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales